identify HIV-infected infants, especially those over the age of 6 months, and as an adjunct to diagnosis of acute HIV infection in adults. We developed a simple enzyme immunoassay for detection of HIV-specific IgA, using standard commercially available reagents. Enzyme immunoassay was comparable to Western blot for detection of HIV-specific IgA in sera from adults (n = 216), older children (n = 49), and infants born to HIV-infected mothers (n = 65). Specificity was 100% and sensitivity ranged from 80 to 92%. IgA-enzyme immunoassay is a simple, highly sensitive method for detection of HIV-specific IgA antibodies and is easily adapted to the standard clinical laboratory.
A number of therapeutic interventions have been shown to be effective in improving the quality and prolonging the duration of life for persons infected with human immunodeficiency virus (HIV) (5, 6, 8, 11, 17, 18, 21) . Prophylaxis for Pneumocystis carinii pneumonia and zidovudine treatment are now routinely recommended for asymptomatic HIVinfected patients with significant immunodeficiency as well as for symptomatic patients. Optimal clinical application of early intervention strategies is, however, dependent on the availability of accurate methods for early HIV diagnosis.
Although many infants and young children may be eligible to receive early interventions, making a definitive diagnosis of HIV infection by standard immunoglobulin G (IgG)-based serologic testing has been problematic during the A number of significant advances have been made in the early diagnosis of HIV infection in infants. Direct viral detection methods, including HIV culture and polymerase chain reaction (PCR), appear to be highly sensitive (>95% after 3 to 6 months of age) and specific (7, 9, 10, (12) (13) (14) 20 using commercially available reagents (Abbott Laboratories, Chicago, Ill.), and results were interpreted by using previously published criteria (4) .
Detection of HIV-specific IgA. Each serum sample was tested in a blinded manner for the presence of HIV-specific IgA, using both Western blot and EIA. Prior to each assay, serum was processed (three times) to deplete IgG by using the Quick-Sep IgM:rProtein G affinity method (IsoLab Inc., Akron, Ohio) as described previously (22) . Fifty microliters of serum was added to the prefilled tube, which was placed on an orbital shaker at room temperature for 30 min. For the second and third repetitions, the buffer from the prefilled tubes was removed to reduce the amount of serum dilution. The final dilution of absorbed serum was 1:10. A subset of the adult serum samples was also tested for IgA by EIA, using unabsorbed serum for comparison.
Western blot for detection of HIV-specific IgA was performed by using a modification of a commercially available HIV-1 immunoblot kit (Bio-Rad Laboratories, Hercules, Calif.), with an affinity-isolated anti-human IgA conjugate (1:2,000 dilution; TAGO Inc., Burlingame, Calif.) substituted for the anti-human IgG conjugate provided with the kit. Blots with p24, gp4l, gpl20, or gpl60 bands appearing on the strips were considered positive (22 Weiblen and associates at the Massachusetts Department of Public Health developed and tested immunoblot methods for HIV-specific IgA detection, using infant serum that had been depleted of interfering IgG by absorption with recombinant protein G (22, 24) . Detection of specific IgA antibodies by immunoblot was highly specific for HIV infection, but sensitivity was age dependent, with the highest sensitivity in infants of >12 months of age. Subsequent studies have confirmed the utility of IgA detection in HIV-exposed infants (15, 19) . Rare, if any, false-positive results have been identified. The sensitivity of the test appears low (6 to 17%) in the newborn period but increases to approximately 80 to 97% after 6 months of age.
Studies performed to date have utilized immunoblot as the standard methodology for detection of HIV-specific IgA antibodies (15, 16, 19, 22, 23 (22) . In contrast, the EIA described here, using commercially available reagents, was more sensitive than standard Western blot methods (88 versus 76%). This may be related to differences in the antigens used. According to the manufacturer, primarily anti-p24 and anti-gp4l antibodies are detected by the commercial kits adapted for our assay. In this initial study, we chose to include only infants who were over the age of 6 
